1268830-74-5

Basic information

• Product Name: methyl 3-amino-2-chloro-6-fluorobenzoate
• Synonyms: methyl 3-amino-2-chloro-6-fluorobenzoate
• CAS NO: 1268830-74-5
• Molecular Weight: 203.6
• Mol File: 1268830-74-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: methyl 3-amino-2-chloro-6-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-amino-2-chloro-6-fluorobenzoate(1268830-74-5)
• EPA Substance Registry System: methyl 3-amino-2-chloro-6-fluorobenzoate(1268830-74-5)

Safety Data

• Hazardous Substances Data: 1268830-74-5(Hazardous Substances Data)

Upstream product

• 434-75-3 2-chloro-6-fluorobenzoic acid 
• 206884-30-2 2-chloro-3-nitro-6-fluoro benzoic acid 
• 67-56-1 methanol 
• 1186194-01-3 3-amino-2-chloro-6-fluorobenzoic acid 
• 2106-02-7 2-chloro-4-fluoroaniline 
• 79-22-1 methyl chloroformate 
• 1268830-73-4 methyl 2-chloro-3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-fluorobenzoate 
• 1153146-10-1 1-(2-chloro-4-fluorophenyl)-2,5-dimethyl-1H-pyrrole 

Downstream Products

• 1268830-75-6 methyl 2-chloro-6-fluoro-3-(propylsulfonamido)benzoate 
• 1269421-22-8 methyl 2-chloro-6-fluoro-3-(3-fluoropropylsulfonamido)benzoate 
• 1269421-23-9 methyl 2-chloro-6-fluoro-3-((3-fluoro-N-((3-fluoropropyl)sulfonyl)propyl)sulfonamido)benzoate 
• 1269421-21-7 2-chloro-6-fluoro-3-(3-fluoropropylsulfonamido)benzoic acid 
• 1186194-00-2 2-chloro-6-fluoro-3-(propylsulfonamido)benzoic acid 
• 1269421-06-8 2-chloro-3-(cyclopropylmethylsulfonamido)-6-fluorobenzoic acid 
• 1269421-08-0 2-chloro-6-fluoro-3-(2-methylpropylsulfonamido)benzoic acid 
• 1357384-85-0 2-chloro-3-(Ν-(propylsulfonyl)propylsulfonamido)-6-fluorobenzoic acid methyl ester 
• 1269420-23-6 4-aminoquinazoline-8-carboxylic acid [2-chloro-6-fluoro-3-(propane-1-sulfonylamino)phenyl]amide 
• 1269421-70-6 4-chloro-N-(2-chloro-6-fluoro-3-(propylsulfonamido)phenyl)quinazoline-8-carboxamide 
• 1268831-13-5 propane-1-sulfonic acid {2-chloro-4-fluoro-3-[3-(3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-4-yl)ureido]phenyl}amide 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF

The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties

Recent clinical data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma. Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low solubility requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures. Through structure-based design, we discovered a new class of highly potent aminopyrimidine-based B-Raf inhibitors with improved solubility and pharmacokinetic profiles. The hinge binding moiety possesses a basic center imparting high solubility at gastric pH, addressing the dissolution limitation observed with our previous series. In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogues 32 and 35 (G945), molecules with desirable physicochemical properties, emerged as lead compounds with strong efficacy in a B-RafV600E mutant mouse xenograft model. Synthesis, SAR, lead selection, and evaluation of key compounds in animal studies will be described.